Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 9/20 | 0.50 |
| ▸ | MAPT | P10636 | 6/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 6/20 | 0.46 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9912178 | 0.83 | MAPT (0.53) | POLBTP53MAPTLMNARXFP1 | |
| SCHEMBL15043471 | 0.82 | POLB (0.48) | POLBTP53MAPTLMNARXFP1 | |
| SCHEMBL24410737 | 0.81 | MEN1 (0.56) | POLBTP53MAPTLMNARXFP1 | |
| SCHEMBL15043478 | 0.79 | POLB (0.51) | POLBTP53MAPTLMNARXFP1 | |
| SCHEMBL9912175 | 0.78 | TP53 (0.53) | POLBTP53MAPTLMNARXFP1 | |
| SCHEMBL21755743 | 0.72 | ADRB2 (0.75) | POLBTP53MAPTLMNAOPRK1 | |
| SCHEMBL20551994 | 0.72 | OPRK1 (0.53) | POLBTP53MAPTLMNAOPRK1 | |
| SCHEMBL3405864 | 0.71 | MAPT (0.48) | MAPTRXFP1GRM2 | |
| SCHEMBL24120919 | 0.71 | TP53 (0.70) | POLBTP53MAPTLMNARXFP1 | |
| SCHEMBL21751220 | 0.70 | ADRB2 (0.50) | POLBTP53MAPTLMNAOPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220144845-A1 | SUBSTITUTED PYRROLO[1,2-a]QUINOXALIN-4(5H)-ONES AS CX3CR1 ANTAGONISTS | UNIV DREXEL (US) | 2022-05-12 | — | — | US | disclosed |
| US-20200062768-A1 | CX3CR1 Small Molecule Antagonists, and Methods Using Same | DREXEL UNIVERSITY | 2020-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144845-A1 | SUBSTITUTED PYRROLO[1,2-a]QUINOXALIN-4(5H)-ONES AS CX3CR1 ANTAGONISTS | CX3CR1, CCR5, CCL2 | POLB 2949/4885TP53 1963/4885MAPT 1006/4885 |
| US-20200062768-A1 | CX3CR1 Small Molecule Antagonists, and Methods Using Same | CX3CR1, CCR5, CXCR3 | POLB 4422/4885TP53 1901/4885MAPT 796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.